CCO Oncology Podcast

189 Epizód

1. Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

   Közzétéve: 2025. 03. 25.
2. Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

   Közzétéve: 2025. 02. 20.
3. Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

   Közzétéve: 2025. 02. 10.
4. Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

   Közzétéve: 2025. 01. 09.
5. Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

   Közzétéve: 2024. 10. 22.
6. Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

   Közzétéve: 2024. 10. 16.
7. ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

   Közzétéve: 2024. 10. 01.
8. A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

   Közzétéve: 2024. 09. 30.
9. Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

   Közzétéve: 2024. 09. 06.
10. Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

    Közzétéve: 2024. 09. 05.
11. ROS1-Alterations and Molecular Testing in Advanced NSCLC

    Közzétéve: 2024. 08. 28.
12. Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

    Közzétéve: 2024. 08. 05.
13. Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

    Közzétéve: 2024. 07. 22.
14. Current Clinical Practice and NCCN Guidelines for CLL/SLL

    Közzétéve: 2024. 07. 18.
15. Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

    Közzétéve: 2024. 07. 12.
16. CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

    Közzétéve: 2024. 07. 11.
17. Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

    Közzétéve: 2024. 07. 09.
18. Congress to Clinic: Expert Takeaways on Emerging Data for AML

    Közzétéve: 2024. 07. 08.
19. Congress to Clinic: Expert Takeaways on Emerging Data for MDS

    Közzétéve: 2024. 07. 05.
20. Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

    Közzétéve: 2024. 05. 14.